全文获取类型
收费全文 | 5288篇 |
免费 | 309篇 |
国内免费 | 22篇 |
专业分类
耳鼻咽喉 | 47篇 |
儿科学 | 183篇 |
妇产科学 | 123篇 |
基础医学 | 582篇 |
口腔科学 | 143篇 |
临床医学 | 392篇 |
内科学 | 1757篇 |
皮肤病学 | 68篇 |
神经病学 | 471篇 |
特种医学 | 113篇 |
外科学 | 661篇 |
综合类 | 19篇 |
一般理论 | 1篇 |
预防医学 | 207篇 |
眼科学 | 27篇 |
药学 | 361篇 |
中国医学 | 7篇 |
肿瘤学 | 457篇 |
出版年
2023年 | 53篇 |
2022年 | 73篇 |
2021年 | 169篇 |
2020年 | 82篇 |
2019年 | 135篇 |
2018年 | 156篇 |
2017年 | 116篇 |
2016年 | 122篇 |
2015年 | 114篇 |
2014年 | 173篇 |
2013年 | 243篇 |
2012年 | 288篇 |
2011年 | 280篇 |
2010年 | 155篇 |
2009年 | 144篇 |
2008年 | 223篇 |
2007年 | 284篇 |
2006年 | 260篇 |
2005年 | 262篇 |
2004年 | 223篇 |
2003年 | 208篇 |
2002年 | 216篇 |
2001年 | 164篇 |
2000年 | 168篇 |
1999年 | 156篇 |
1998年 | 45篇 |
1997年 | 45篇 |
1996年 | 42篇 |
1995年 | 43篇 |
1994年 | 38篇 |
1993年 | 31篇 |
1992年 | 101篇 |
1991年 | 60篇 |
1990年 | 76篇 |
1989年 | 61篇 |
1988年 | 57篇 |
1987年 | 65篇 |
1986年 | 50篇 |
1985年 | 53篇 |
1984年 | 45篇 |
1983年 | 52篇 |
1982年 | 20篇 |
1979年 | 25篇 |
1978年 | 19篇 |
1976年 | 16篇 |
1975年 | 25篇 |
1974年 | 26篇 |
1971年 | 16篇 |
1970年 | 20篇 |
1968年 | 15篇 |
排序方式: 共有5619条查询结果,搜索用时 15 毫秒
991.
992.
Arcaini L Colombo N Bernasconi P Calatroni S Passamonti F Orlandi E Bonfichi M Burcheri S Porta MD Rumi E Montanari F Algarotti A Pascutto C Lazzarino M 《Leukemia & lymphoma》2006,47(6):1018-1022
Bcl-2/IgH rearrangement is the molecular hallmark of follicular lymphoma which is present in 70 - 90% of cases at diagnosis. The significance of the bcl-2 rearrangement at onset of disease and of its clearing after treatment (molecular response) is still controversial.
The aims of the present analysis are: to evaluate the incidence of bcl-2 rearrangement in blood and marrow in a cohort of patients systematically investigated at diagnosis, to describe the correlation between bcl-2 and presenting features, to clarify the correlation of molecular response with outcome.
Of 98 patients studied at initial staging for the presence of bcl-2 rearrangement, 64 (65%) showed bcl-2/IgH rearrangement in peripheral blood (PB) and/or bone marrow (BM) (58 at Major Breakpoint Region, MBR, and 6 at minor cluster region, mcr) while no bcl-2/IgH rearrangement was detected in the remaining 34 (35%) (germline status). No statistically significant differences were found between bcl-2 positive and bcl-2 negative cases as concerns presenting clinical features and response to first-line therapy. The median event-free survival, EFS, was not reached for the bcl-2 negative patients in PB and was 11 months for bcl-2 positive patients (statistically significant, P = 0.01) and, similarly, the median EFS was not reached for the bcl-2 negative patients in BM and was 11 months for bcl-2 positive patients (statistically significant, P = 0.04).
Of the 64 bcl-2 positive cases, patients were analysed for molecular response (48 in BM and 40 in PB): 16 were molecular responders in BM and 20 were molecular responders in PB. The median EFS was 19 months for molecular responders in PB and 9 months for non-responders; 1-year-EFS was 68% (95% CI; 49 - 88), for responders in PB and 42% (95% CI; 22 - 61) for non-responders (P = 0.05). The median EFS was 11 months both for molecular responders and non-responders in BM; 1-year-EFS was 52% for responders in BM (CI; 30 - 73), and 43% (CI 33 - 71) for non-responders (P = 0.7). No clinical feature showed significant correlation with PB and BM molecular responses.
This analysis shows that bcl-2 rearrangement in blood and bone marrow is frequently detected at staging, even in stage I disease. Absence of the bcl-2 rearrangement is related to a better EFS and the achievement of a molecular response in peripheral blood after therapy is associated with a better EFS. 相似文献
The aims of the present analysis are: to evaluate the incidence of bcl-2 rearrangement in blood and marrow in a cohort of patients systematically investigated at diagnosis, to describe the correlation between bcl-2 and presenting features, to clarify the correlation of molecular response with outcome.
Of 98 patients studied at initial staging for the presence of bcl-2 rearrangement, 64 (65%) showed bcl-2/IgH rearrangement in peripheral blood (PB) and/or bone marrow (BM) (58 at Major Breakpoint Region, MBR, and 6 at minor cluster region, mcr) while no bcl-2/IgH rearrangement was detected in the remaining 34 (35%) (germline status). No statistically significant differences were found between bcl-2 positive and bcl-2 negative cases as concerns presenting clinical features and response to first-line therapy. The median event-free survival, EFS, was not reached for the bcl-2 negative patients in PB and was 11 months for bcl-2 positive patients (statistically significant, P = 0.01) and, similarly, the median EFS was not reached for the bcl-2 negative patients in BM and was 11 months for bcl-2 positive patients (statistically significant, P = 0.04).
Of the 64 bcl-2 positive cases, patients were analysed for molecular response (48 in BM and 40 in PB): 16 were molecular responders in BM and 20 were molecular responders in PB. The median EFS was 19 months for molecular responders in PB and 9 months for non-responders; 1-year-EFS was 68% (95% CI; 49 - 88), for responders in PB and 42% (95% CI; 22 - 61) for non-responders (P = 0.05). The median EFS was 11 months both for molecular responders and non-responders in BM; 1-year-EFS was 52% for responders in BM (CI; 30 - 73), and 43% (CI 33 - 71) for non-responders (P = 0.7). No clinical feature showed significant correlation with PB and BM molecular responses.
This analysis shows that bcl-2 rearrangement in blood and bone marrow is frequently detected at staging, even in stage I disease. Absence of the bcl-2 rearrangement is related to a better EFS and the achievement of a molecular response in peripheral blood after therapy is associated with a better EFS. 相似文献
993.
Colombo D Compostella F Ronchetti F Scala A Toma L Tokuda H Nishino H 《European journal of medicinal chemistry》2000,35(12):1109-1113
The in vitro anti-tumor promoting effect of monohexanoates of 2-O-alpha-D-gluco- and galactopyranosyl-sn-glycerol on the 12-O-tetradecanoylphorbol-13-acetate (TPA) induced Epstein-Barr virus early antigen (EBV-EA) activation was evaluated and compared to the potencies of the corresponding beta-anomers. The results show that the inversion of the anomeric configuration from beta to alpha does not seem to significantly influence the activity, which is present, as for the beta-anomers, even at 1x10 mol ratio without any cytotoxicity. 相似文献
994.
Katia Falasca Jacopo Vecchiet Claudio Ucciferri Marta Di Nicola Chiara D’Angelo Marcella Reale 《Nutrients》2015,7(10):8335-8347
Inflammation persists in patients infected with HIV. Reduction of inflammatory cytokines and microbial translocation might be one way that this could be managed. Purpose: The anti-inflammatory properties of certain probiotic strains prompted us to investigate whether a probiotic could reduce the inflammatory index of HIV-infected patients. Methods: The study involved 30 HIV+ males on antiretroviral therapy, who were given one bottle of fermented milk Yakult Light® containing Lactobacillus casei Shirota (LcS) twice a day for four weeks. Results: The probiotic LcS was associated with an increase of T lymphocytes and a significant increase of CD56+ cells (p = 0.04). There was also a significant decrease of mRNA levels of TGFβ, IL-10 and IL-12 (p < 0.001) and IL-1β expression (p < 0.001) and an increase of serum IL-23 (p = 0.03). In addition, decreased inflammation and cardiovascular risk were observed, as shown by a reduction of cystatin C (p < 0.001). Conclusions: These data provide preliminary evidence that probiotic supplementation may modulate certain immunological parameters and some of the cytokines that were analyzed. Thus, we propose that LcS may be an inexpensive and practical strategy to support the immune function of HIV+ patients. 相似文献
995.
996.
997.
Neurological symptoms in essential thrombocythemia: impact of JAK2V617F mutation and response to therapy 下载免费PDF全文
Andrea Aroldi Caterina Cecchetti Arianna Colombo Leonardo Cattaneo Pietro Enrico Pioltelli Enrico Maria Pogliani Elena Maria Elli 《European journal of haematology》2016,96(6):593-601
Patients with essential thrombocythemia (ET) often suffer from neurological symptoms (NS) not ever resulting from previous thrombotic cerebral events (TCE). We reported NS occurred in 282 patients, in order to identify the factors influencing ET‐related NS in the absence of TCE, and the response to therapy. Overall, 116 of 282 patients (41%) presented NS; 101 of them (87%) reported subjective transient and fluctuating NS, without concurrent TCE, which we defined as ET‐related NS, by frequency: cephalalgia, chronic paresthesias, dizziness or hypotension, visual disturbances, and tinnitus. In univariate analysis, ET‐related NS resulted more frequently in young people (P = 0.017) and in females (P = 0.025). We found a higher prevalence of JAK2V617F mutation in ET‐related NS patients (P = 0.021). In multivariate analysis, gender (P = 0.024) and JAK2V617F mutation (P = 0.041) remained significantly associated with the development of ET‐related NS, with a risk of about four times higher for JAK2V617F‐mutated patients (OR = 3.75). Ninety‐seven of 101 patients with ET‐related NS received an antiplatelet (AP) agent at the time of NS, whereas only selected high‐risk ET‐related NS patients were treated with a cytoreductive drug, according to the published guidelines and similarly to patients without NS. We observed that only 32 of 97 (33%) patients with ET‐related NS achieved a complete response after AP treatment. Among the 65 non‐responder patients, 36 (55.4%) improved NS after the introduction of cytoreductive therapy; therefore, the addition of cytoreductive treatment should be considered in this setting. 相似文献
998.
High rate of hematological responses to sorafenib in FLT3‐ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation 下载免费PDF全文
Tiago De Freitas Sarah Marktel Simona Piemontese Matteo G. Carrabba Cristina Tresoldi Carlo Messina Maria Teresa Lupo Stanghellini Andrea Assanelli Consuelo Corti Massimo Bernardi Jacopo Peccatori Luca Vago Fabio Ciceri 《European journal of haematology》2016,96(6):629-636
Relapse represents the most significant cause of failure of allogeneic hematopoietic stem cell transplantation (HSCT) for FLT3‐ITD‐positive acute myeloid leukemia (AML), and available therapies are largely unsatisfactory. In this study, we retrospectively collected data on the off‐label use of the tyrosine kinase inhibitor sorafenib, either alone or in association with hypomethylating agents and adoptive immunotherapy, in 13 patients with post‐transplantation FLT3‐ITD‐positive AML relapses. Hematological response was documented in 12 of 13 patients (92%), and five of 13 (38%) achieved complete bone marrow remission. Treatment was overall manageable in the outpatient setting, although all patients experienced significant adverse events, especially severe cytopenias (requiring a donor stem cell boost in five patients) and typical hand‐foot syndrome. None of the patients developed graft‐vs.‐host disease following sorafenib alone, whereas this was frequently observed when this was given in association with donor T‐cell infusions. Six patients are alive and in remission at the last follow‐up, and four could be bridged to a second allogeneic HSCT, configuring a 65 ± 14% overall survival at 100 d from relapse. Taken together, our data suggest that sorafenib might represent a valid treatment option for patients with FLT3‐ITD‐positive post‐transplantation relapses, manageable also in combination with other therapeutic strategies. 相似文献
999.
Dallaspezia S Benedetti F Colombo C Barbini B Fulgosi MC Gavinelli C Smeraldi E 《Journal of affective disorders》2012,138(3):337-342
BackgroundLight Therapy (LT) when combined with standard antidepressant treatment for unipolar depression hastens recovery. We studied the influence of LT timing on the antidepressant efficacy of LT and the influence of the season of treatment and recurrence on the response to treatment.MethodsWe studied 70 inpatients affected by Unipolar Depression, treated for three weeks with combined LT and venlafaxine. Two-third of the patients received LT following a predictive algorithm based on MEQ scores; the others received LT at 11:00 a.m. Severity of depression was rated on the Hamilton Depression Rating Scale (HDRS). A subgroup of patients wore activity monitors.ResultsHDRS scores significantly decreased during treatment (Friedman's ANOVA: χ2 = 186.82, p < 0.00001). LT administered in the early morning showed a better relative efficacy than late morning (F = 4.576; p = 0.012) with the clinical improvement correlating with an advance in rest–activity rhythm acrophase (r = ? 0.336; p = 0.017). Season of hospitalization interacted with LT timing and time in influencing response to treatment (F = 3.101; p = 0.049) and season of episode recurrence significantly interacted with LT timing, season of hospitalization and time (F = 5.925; p = 0.0035).LimitationsThe major limitation of the study is the small sample size when considering simultaneously LT schedules, season of treatment and recurrence. Moreover, even if none of the patients fulfilled DSM-IV criteria for seasonal pattern of recurrence, they were not administered any questionnaire about seasonality.ConclusionsWe confirmed the usefulness of LT as a non-pharmacological antidepressant therapy for non-seasonal depression. Season and timing of administration and timing of the rest–activity cycle affected response to treatment. 相似文献
1000.
Federica Ungaro Piergiuseppe Colombo Luca Massimino Giovanni Stefano Ugolini Carmen Correale Marco Rasponi Valentina Garlatti Federica Rubbino Carlotta Tacconi Paola Spaggiari Antonino Spinelli Michele Carvello Matteo Sacchi Salvatore Spanò Stefania Vetrano Alberto Malesci Laurent Peyrin-Biroulet Silvio Danese Silvia D'Alessio 《International journal of cancer. Journal international du cancer》2019,145(7):1913-1920